China Medical System Holdings Ltd.
1.24
EUR
0.00
(0.00%)
ISIN
KYG211081248
CUSIP
G21108124
Return %
Stock
S&P 500
1Y
-15.65
14.20
3Y
-2.36
81.12
5Y
-21.02
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Kong Lam
- Full Time Employees
- 6,415
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Island Place Tower Shenzhen GD China
- IPO Date
- Sep 28, 2010
- Website
- web.cms.net.cn
- Similar Companies
- Business
- China Medical System Holdings Limited China Medical System Holdings Limited (0867.HK), an investment holding company founded in 1995 and headquartered in North Point, Hong Kong, primarily engages in the research, development, production, marketing, promotion, and sale of pharmaceutical products with a focus on cardio-cerebrovascular, gastroenterology, ophthalmology, dermatology, medical aesthetics, and other specialty therapeutic areas; its core marketed products include the innovative drugs LUMEBLUE (Methylthioninium Chloride Enteric-coated Sustained-release Tablets for colonoscopy lesion detection), METOJECT (pre-filled methotrexate injection for psoriasis and rheumatoid arthritis), VELPHORO (iron-based phosphate binder for chronic kidney disease), ILUMETRI (IL-23 inhibitor monoclonal antibody for psoriasis), and VALTOCO (diazepam nasal spray for epilepsy seizure clusters), alongside established brands such as Deanxit, Ursofalk, Plendil, XinHuoSu, Cystistat, Nesiritide, Augentropfen Stulln Mono eye-drops, GanFuLe, and Salofalk, as well as promotion services for in-licensed medicines from overseas and domestic partners sold to wholesalers, distributors, and hospitals primarily in Mainland China, with expanding operations into Hong Kong, Macau, Southeast Asia, Australia, and New Zealand. The company operates through segments including marketing and promotion of pharmaceutical products and other businesses encompassing production and sales of medicines and medical instruments, targeting unmet clinical needs via collaborations with global biotech and biopharma firms, and maintains a diversified portfolio enriched by non-National Volume-Based Procurement (VBP) exclusive and innovative products that accounted for over half of direct-sale revenue in 2024. Recent major developments include approvals for LUMEBLUE marketing and METOJECT's additional rheumatoid arthritis indication in 2024, NDA acceptances for Desidustat Tablets (HIF-PHI for CKD anemia) and ruxolitinib cream (JAK inhibitor for vitiligo), progression of over 10 clinical trials such as Y-3 (stroke cytoprotectant), VEGFA/ANG2 bispecific antibody (nAMD), TYK2 inhibitor CMS-D001 (psoriasis/AD), GnRH antagonist CMS-D002 (endometriosis), and GLP-1R/GCGR dual agonist CMS-D005 (obesity); new collaborations in 2024 and 2025 encompass exclusive licenses with Incyte for povorcitinib (JAK1 inhibitor for vitiligo/hidradenitis suppurativa), Atom Therapeutics for ABP-671 (gout/hyperuricemia), Alpha Cognition for ZUNVEYL (Alzheimer's dementia), Mabgeek Biotech for MG-K10 (long-acting anti-IL-4Rα for atopic dermatitis), Chongqing Genrix for vecantoxatug and silevimig injections, and Novartis for Lucentis and Beovu ophthalmic drugs via subsidiary CMS Vision, plus three new medical aesthetic injectables (Polycaprolactone Microsphere Gel, Calcium Hydroxylapatite Microsphere Gel, Decellularized Extracellular Matrix Implant); additionally, a secondary listing on the Singapore Exchange mainboard in July 2025 to expand in Southeast Asia, alongside strategic shifts toward product innovation, commercial model reform (in-hospital/out-of-hospital, online/offline channels), and international growth, with five innovative drugs now commercialized and a pipeline of nearly 40 first-in-class/best-in-class candidates. China Medical System Holdings Limited is a subsidiary of Treasure Sea Limited and continues to build end-to-end innovation capabilities, with H1 2025 revenue and profit growth reported amid these advancements.
Company News
CMS(867.HK/8A8.SG): Innovative Drug Lumirix® Approved in China for Additional Indication of Atopic Dermatitis (AD)
China Medical System (CHSYF) to Release Quarterly Earnings on Monday